DENVER, Colo., Nov 11, 2025 (247marketnews.com)- Quoin Pharmaceuticals (NASDAQ:QNRX) successfully achieved target loading concentrations for two proprietary topical rapamycin delivery technologies. The company reported rapamycin loadings of 4% w/w for its topical lotion and 5% w/w for its dermal patch system, a milestone that positions Quoin to begin clinical trial and stability batch manufacturing in the fourth quarter of 2025.
Quoin expects clinical testing to begin in the first half of 2026 across several indications, including Microcystic Lymphatic Malformations and Venous Malformations, both of which currently have no FDA-approved treatments. The company believes the ability to achieve these high target loadings will provide competitive advantages in optimizing drug delivery at the site of disease compared to other topical formulations in development.
Chief Executive Officer Dr. Michael Myers called the development a “very significant milestone” for Quoin’s rapamycin programs, noting that the new delivery systems “could potentially provide competitive advantages over other topical rapamycin formulations.” He added that the programs are complementary to Quoin’s late-stage Netherton Syndrome and Peeling Skin Syndrome studies, which continue to progress following the company’s recent capital raise.
With its new formulations on track for clinical advancement, Quoin enters year-end 2025 in a strong position, advancing multiple late-stage and early clinical programs aimed at addressing serious dermatological disorders with high unmet need.
The post Quoin Pharmaceuticals Hits Key Formulation Milestone for Topical Rapamycin Programs appeared first on 24/7 MarketNews.